Снижение сердечно-сосудистой смертности: как работают способы улучшения приверженности лечению в эпоху трансляционной медицины

1. Эл. ресурс: https://www.gks.ru/folder/12781 [Available from: https://www.gks.ru/folder/12781 (In Russ.)].
2. Эл. ресурс: https://www.rosminzdrav.ru/poleznye-resursy/natsproektzdravoohranenie/bssz [Available from: https://www.rosminzdrav.ru/poleznye-resursy/natsproektzdravoohranenie/bssz (In Russ.)].
3. Steg Ph, Bhatt D, Wilson P, et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA. 2007;297:1197-206. 
4. Murray CJL, Lopez LD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-504. 
5. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. Eur Heart J. 2020;41(3):407-77. doi: 10.1093/eurheartj/ehz425
6. Davidoff F, Batalden P. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement. http://www.strobe-
statement.org. Accessed June 26, 2006.
7. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269-76
8. Kotseva K, De Backer G, De Backer D, et al. Lifestyle and Impact on Cardiovascular Risk Factor Control in Coronary Patients Across 27 Countries: Results From the European Society of Cardiology ESC-EORP EUROASPIRE V Registry. Eur J Prev Cardiol. 2019;26(8):824-35. doi: 10.1177/2047487318825350
9. Bakke Å, Dalen I, Thue G, et al. Variation in the Achievement of HbA1c, Blood Pressure and LDL Cholesterol Targets in Type 2 Diabetes in General Practice and Characteristics Associated With Risk Factor Control. Diabet Med. 2019. doi: 10.1111/dme.14159
10. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. 
11. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. 
12. Aradi D, Storey RF, Komocsi A, et al. Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209-15. 
13. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005;257:399-414. doi: 10.1111/j.1365-2796.2005.01477.x
14. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-7. doi: 10.1161/01
15. Herlitz J, Tóth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10:125-41. doi: 10.2165/11318440-000000000-00000
16. Rodríguez LA, Cea-Soriano L, Martín-Merino E, et al. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011;343:d4094. 
17. Sundstrom J, Hedberg J, Thuresson M, et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events A Swedish Nationwide, Population-Based Cohort Study. Circulation. 2017;136:1183-92. doi: 10.1161/CIRCULATIONAHA.117.028321
18. Newby L, LaPoint N, Chen A, et al. Long-term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease. Circulation. 2006:17;113(2):203-12. 
19. Biondi-Zoccai G, Lotrionte M, Agostoni P. A Systematic Review and Meta-Analysis on the Hazards of Discontinuing or Not Adhering to Aspirin Among 50,279 Patients at Risk for Coronary Artery Disease. Eur Heart J. 2006;27(22):2667-74. 
20. Bansilal S, Castellano J, Garrido E, et al. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. J Am Coll Cardiol. 2016;68(8):789-801. 
21. Лупанов В.П. Роль ацетилсалициловой кислоты в профилактике атеросклероза и его осложнений. Рус. мед. журн. 2007;15(16):1245-8 [Loupanov V. The role of acetylsalicylic acid in the prevention of atherosclerosos and its complications. Russian Med J. 2007;15(16):1245-8 (In Russ.)]. 
22. Жиров И.В. Длительная терапия ацетилсалициловой кислотой. Как избежать возможных осложнений? Рациональная фармакотерапия в кардиологии. 2010;5:703-8 [Zhirov I. Long-term treatment of acetylsalicylic acid. How can we escape from potential complications? Rational Pharmacother Cardiol. 2010;5:703-8 (In Russ.)]. 
23. Багликов А.Н., Рафальский В.В. Значение приверженности пациентов к лечению при длительном приеме АСК у пациентов, перенесших острый коронарный синдром: результаты исследования ФОРПОСТ. Кардиология. 2012;9(52):22-8 [Baglikov A, Rafalsky V. The Value of Compliance During Chronic Administration of Acetylsalicylic Acid In Patients With Acute Coronary Syndrome: Results of The Study "FORPOST". Kardiologiia. 2012;9(52):22-8 (In Russ.)]. 
24. Kim H-S, Kim H, Lee H, et al. Analysis and comparison of statin prescription patterns and outcomes according to clinical department. J Clin Pharm Ther. 2016;41:70-7. doi: 10.1111/jcpt.12350
25. Jennings C, Kotseva K, DeBacquer D, et al.; on behalf of EUROACTION PLUS Study Group. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: The EUROACTION PLUS Varenicline trial. Eur Heart J. 2014;35:1411-20. doi: 10.1093/
eurheartj/ehu051
26. Chow CK, Jolly S, Rao-Melacini P, et al.; Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121:750-8. 
27. Minneboo M, Lachman S, Snaterse M, et al. on behalf of the RESPONSE-2 Study Group. Community-based lifestyle intervention in patients with coronary artery disease: The RESPONSE-2 Trial. J Am Coll Cardiol. 2017;70:318-27. doi: 10.1016/j.jacc.2017.05.041
28. Wood DA, Kotseva K, Connolly S, et al.; on behalf of EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: A paired, cluster-randomised controlled trial. Lancet. 2008;371:1999-2012. 
29. Lafeber M, Spiering W, van der Graaf Y, et al. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. Am Heart J. 2013;166:282-9. 
30. Lafeber M, Grobbee DE, Schrover IM, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2015;181:193-9. 
31. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22:920-30. 
32. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339
33. Zedler B, Kakad P, Colilla S, et al. Does Packaging With a Calendar Feature Improve Adherence to Self-Administered Medication for Long-Term Use? A Systematic Review. Clin Ther. 2011;33:62-73. 
34. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Совр. ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, 
et al. Clinical guidelines "Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice". Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23
35. Булахова Е.Ю., Кореннова О.Ю., Козырева В.А. и др. Возможности снижения развития гастродуоденальных осложнений при длительном использовании препаратов ацетилсалициловой кислоты. Кардиоваскулярная терапия и профилактика. 2010;9(4):41-4 [Bulakhova EYu, Korennova OYu, Kozyreva VA, et al. Reduction of gastro-intestinal adverse effect risk in long-term therapy with acetylsalicylic acid. Cardiovascular Therapy and Prevention. 2010;9(4):41-4 (In Russ.)]. 
36. Некрасов А.А., Тимощенко Е.С., Ерофеева С.Г. и др. Безопасность и эффективность применения различных форм АСК у больных со стабильной ИБС и высоким риском развития гастропатий по данным 
6-месячного проспективного исследования. Кардиология. 2019;59(S3):43-51 [Nekrasov AA, Timoshchenko ES, Erofeeva SG, et al. Safety and efficacy of treatment with other forms of acetylsalicylic acid in the patients with coronary heart disease and high risk of development of gastropathies on the data of 6 months prospective study. Kardiologiia. 2019;59(3S):43-51 (In Russ.)]. 
37. Adherence to long-term therapies. Evidence for actions. WHO, 2003.
38. Haynes RB. Interventions for helping patients to follow prescriptions for medications. Cochrane Database System Rev. 2002;2:CD000011. doi: 10.1002/14651858.CD000011

________________________________________________

1. Available from: https://www.gks.ru/folder/12781 (In Russ.)
2. Available from: https://www.rosminzdrav.ru/poleznye-resursy/natsproektzdravoohranenie/bssz (In Russ.)
3. Steg Ph, Bhatt D, Wilson P, et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA. 2007;297:1197-206. 
4. Murray CJL, Lopez LD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-504. 
5. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. Eur Heart J. 2020;41(3):407-77. doi: 10.1093/eurheartj/ehz425
6. Davidoff F, Batalden P. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement. http://www.strobe-
statement.org. Accessed June 26, 2006.
7. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269-76
8. Kotseva K, De Backer G, De Backer D, et al. Lifestyle and Impact on Cardiovascular Risk Factor Control in Coronary Patients Across 27 Countries: Results From the European Society of Cardiology ESC-EORP EUROASPIRE V Registry. Eur J Prev Cardiol. 2019;26(8):824-35. doi: 10.1177/2047487318825350
9. Bakke Å, Dalen I, Thue G, et al. Variation in the Achievement of HbA1c, Blood Pressure and LDL Cholesterol Targets in Type 2 Diabetes in General Practice and Characteristics Associated With Risk Factor Control. Diabet Med. 2019. doi: 10.1111/dme.14159
10. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. 
11. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. 
12. Aradi D, Storey RF, Komocsi A, et al. Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209-15. 
13. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005;257:399-414. doi: 10.1111/j.1365-2796.2005.01477.x
14. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-7. doi: 10.1161/01
15. Herlitz J, Tóth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10:125-41. doi: 10.2165/11318440-000000000-00000
16. Rodríguez LA, Cea-Soriano L, Martín-Merino E, et al. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011;343:d4094. 
17. Sundstrom J, Hedberg J, Thuresson M, et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events A Swedish Nationwide, Population-Based Cohort Study. Circulation. 2017;136:1183-92. doi: 10.1161/CIRCULATIONAHA.117.028321
18. Newby L, LaPoint N, Chen A, et al. Long-term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease. Circulation. 2006:17;113(2):203-12. 
19. Biondi-Zoccai G, Lotrionte M, Agostoni P. A Systematic Review and Meta-Analysis on the Hazards of Discontinuing or Not Adhering to Aspirin Among 50,279 Patients at Risk for Coronary Artery Disease. Eur Heart J. 2006;27(22):2667-74. 
20. Bansilal S, Castellano J, Garrido E, et al. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. J Am Coll Cardiol. 2016;68(8):789-801. 
21. Loupanov V. The role of acetylsalicylic acid in the prevention of atherosclerosos and its complications. Russian Med J. 2007;15(16):1245-8 (In Russ.)
22. Zhirov I. Long-term treatment of acetylsalicylic acid. How can we escape from potential complications? Rational Pharmacother Cardiol. 2010;5:703-8 (In Russ.)
23. Baglikov A, Rafalsky V. The Value of Compliance During Chronic Administration of Acetylsalicylic Acid In Patients With Acute Coronary Syndrome: Results of The Study "FORPOST". Kardiologiia. 2012;9(52):22-8 (In Russ.)
24. Kim H-S, Kim H, Lee H, et al. Analysis and comparison of statin prescription patterns and outcomes according to clinical department. J Clin Pharm Ther. 2016;41:70-7. doi: 10.1111/jcpt.12350
25. Jennings C, Kotseva K, DeBacquer D, et al.; on behalf of EUROACTION PLUS Study Group. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: The EUROACTION PLUS Varenicline trial. Eur Heart J. 2014;35:1411-20. doi: 10.1093/
eurheartj/ehu051
26. Chow CK, Jolly S, Rao-Melacini P, et al.; Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121:750-8. 
27. Minneboo M, Lachman S, Snaterse M, et al. on behalf of the RESPONSE-2 Study Group. Community-based lifestyle intervention in patients with coronary artery disease: The RESPONSE-2 Trial. J Am Coll Cardiol. 2017;70:318-27. doi: 10.1016/j.jacc.2017.05.041
28. Wood DA, Kotseva K, Connolly S, et al.; on behalf of EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: A paired, cluster-randomised controlled trial. Lancet. 2008;371:1999-2012. 
29. Lafeber M, Spiering W, van der Graaf Y, et al. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. Am Heart J. 2013;166:282-9. 
30. Lafeber M, Grobbee DE, Schrover IM, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2015;181:193-9. 
31. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22:920-30. 
32. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339
33. Zedler B, Kakad P, Colilla S, et al. Does Packaging With a Calendar Feature Improve Adherence to Self-Administered Medication for Long-Term Use? A Systematic Review. Clin Ther. 2011;33:62-73. 
34. Karateev AE, Nasonov EL, Yakhno NN, 
et al. Clinical guidelines "Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice". Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.) doi: 10.14412/1996-7012-2015-1-4-23
35. Bulakhova EYu, Korennova OYu, Kozyreva VA, et al. Reduction of gastro-intestinal adverse effect risk in long-term therapy with acetylsalicylic acid. Cardiovascular Therapy and Prevention. 2010;9(4):41-4 (In Russ.)
36. Nekrasov AA, Timoshchenko ES, Erofeeva SG, et al. Safety and efficacy of treatment with other forms of acetylsalicylic acid in the patients with coronary heart disease and high risk of development of gastropathies on the data of 6 months prospective study. Kardiologiia. 2019;59(3S):43-51 (In Russ.)
37. Adherence to long-term therapies. Evidence for actions. WHO, 2003.
38. Haynes RB. Interventions for helping patients to follow prescriptions for medications. Cochrane Database System Rev. 2002;2:CD000011. doi: 10.1002/14651858.CD000011

И.В. Жиров

1 ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия

________________________________________________

I.V. Zhirov 

1 National Medical Research Center for Cardiology, Moscow, Russia;
2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia